QL1706 + S-1 + oxaliplatin

QL1706 + S-1 + oxaliplatin is a combination regimen under clinical investigation for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) and other cancers. - **QL1706** is a bifunctional monoclonal antibody developed by Qilu Pharmaceutical that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), providing dual immune checkpoint blockade to enhance anti-tumor immune responses[1][2][5][6]. - **S-1** is an oral fluoropyrimidine-based chemotherapy composed of tegafur (a prodrug of 5-fluorouracil), gimeracil, and oteracil potassium; it acts as an antimetabolite inhibiting DNA synthesis in rapidly dividing cells. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in cancer cells. This combination leverages immunotherapy with dual checkpoint inhibition alongside cytotoxic chemotherapy to maximize anti-tumor efficacy. Clinical studies have shown promising activity for regimens containing QL1706 plus chemotherapy in NSCLC and other solid tumors[4][8].

Other names

iparomlimab and tuvonralimab